

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1-16 (canceled).

Claim 17 (currently amended): A method for vaccinating a human against a human immunodeficiency virus comprising the step of:

administering a completely inactivated form of the virus or completely attenuated form of the virus, wherein the attenuated form of the virus lacks a portion of a gene coding for a gag nucleocapsid protein, to said human in an amount of from 10 femtograms to less than 1 picogram.

~~administering to said human an amount of an immunogen comprising an attenuated form of said human immunodeficiency virus sufficient to induce a cell mediated response against said human immunodeficiency virus but below the amount necessary to induce an offsetting humoral response to said human immunodeficiency virus.~~

Claims 18-39 (canceled).

Claim 40 (previously presented): The method of claim 17, wherein the human immunodeficiency virus is HIV-1.

Claim 41 (previously presented): The method of claim 17, wherein the human immunodeficiency virus is HIV-2.

Claims 42 and 43 (canceled).

Claim 44 (currently amended): The method of claim 17, wherein the ~~immunogen~~ attenuated or inactivated form of the virus is administered to the mucosa.

Claims 45 - 46 (canceled).

Claim 47 (new): A method of claim 17, wherein the amount is sufficient to induce a cell mediated response against said human immunodeficiency virus as determined in a

Appl. No. 09/769,223

PATENT

Amdt. dated March 4, 2005

Reply to Office Action of October 6, 2004

HIV antigen-stimulated T-cell proliferation assay but below the amount necessary to induce an offsetting humoral response to said human immunodeficiency virus as determined by the absence of anti-HIV antibodies.